The ideas were all conceived by scientists in Nottingham – one about blood and two about eyes. And all have found potential financial backers after presentations to the newly-formed Nottingham Angels Network.
EXONATE is the brainchild of David Bates, a professor of oncology at the QMC. Prof Bates believes he can develop molecule-based eye drops, making the once-a-month injections unnecessary for wet age-related macular degeneration, the commonest form of blindness in the western world, with 30 million sufferers worldwide.
University of Nottingham spin-out business, Exonate, which specialises in the discovery and development of novel drugs, has received funding of over £400,000 from Fusion IP PLC, IP Group PLC, The University of Nottingham and a syndicate of business angels, including the newly formed Nottingham Angels Network.